Tomas Papajik, MD

Prof, MD., head of institution
Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Czech Republic

Poster(s):

• 1516 - Real-World Outcomes of Idelalisib in Relapsed/Refractory CLL Including High-Risk Patients and Post-BTKi/BCL2 Therapy: A Single-Center Experience from 2016 to 2025

• 1526 - Ibrutinib and acalabrutinib in the treatment of relapsed/refractory chronic lymphocytic leukemia: a real-world analysis from the Czech Chronic Lymphocytic Leukemia Patients Registry